expert medical events Registration and information: www.expertmedicalevents.com ORGANIZING COMMITTEE Etienne Chatelut, PharmD, PhD Institut Claudius-Regaud, Toulouse, France George Demetri, MD Harvard Medical School Boston, MA, USA Nielka van Erp, PharmD, PhD Radboudumc Nijmegen, the Netherlands - chair 2015 Howard Gurney, MB, BS, FRACP Macquarie University and Westmead Hospital, Sydney, Australia Ron Mathijssen, MD, PhD Erasmus Medical Center Rotterdam, the Nethelands Herbie Newell, PhD Newcastle University Newcastle, United Kingdom Mark Ratain, MD The University of Chicago Chicago, IL, USA - chair 2015 Michelle Rudek, PharmD, PhD Johns Hopkins University Baltimore, MD, USA 1 ST INTERNATIONAL WORKSHOP ON AMSTERDAM, THE NETHERLANDS • 23 - 24 MARCH 2015 DOSE OPTIMIZATION STRATEGIES FOR TARGETED DRUGS FOCUS ON ONCOLYTICS Free registration for young investigators with accepted abstracts! WHY SHOULD YOU ATTEND? • This workshop is intended as a compact, focused meeting to encourage crossdisciplinary scientific dialogue and in-depth discussions among all attendees, including presenters. • This meeting is a stepping stone for young medical professionals to present their research in an informal and encouraging setting. We encourage their participation by offering them a complimentary registration (for more information see meeting website). • You will have a great opportunity to meet your international colleagues and expand your network in the beautiful surroundings of Amsterdam! WHO SHOULD ATTEND? Medical oncologists, internal medicine doctors, clinical pharmacologists, hospital pharmacists, industry researchers, government representatives and other experts involved in this field of research. ABSTRACT SUBMISSION We invite you to submit your research on the following topics: • Pharmacokinetics and Pharmacodynamics of Approved and New targeted oncolytics • Population pharmacokinetics & pharmacokinetic-pharmacodynamic modeling • Drug development and optimization: approaches & tools • Drug-drug and drug-disease state interactions • Targeted oncolytics therapies in special populations Abstract submission deadline: 1 February 2015
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
expertmedical eventsRegistration and information: www.expertmedicalevents.com
ORGANIZING COMMITTEE
Etienne Chatelut, PharmD, PhD Institut Claudius-Regaud, Toulouse, France
George Demetri, MD Harvard Medical School Boston, MA, USA
Nielka van Erp, PharmD, PhD Radboudumc Nijmegen, the Netherlands - chair 2015
Howard Gurney, MB, BS, FRACP Macquarie University and Westmead Hospital, Sydney, Australia
Ron Mathijssen, MD, PhD Erasmus Medical Center Rotterdam, the Nethelands
Herbie Newell, PhD Newcastle University Newcastle, United Kingdom
Mark Ratain, MD The University of Chicago Chicago, IL, USA - chair 2015
Michelle Rudek, PharmD, PhD Johns Hopkins University Baltimore, MD, USA
1ST INTERNATIONAL WORKSHOP ON
AMSTERDAM, THE NETHERLANDS • 23 - 24 MARCH 2015
DOSE OPTIMIZATION STRATEGIESFOR TARGETED DRUGSFOCUS ON ONCOLYTICS
Free registration for young investigators with accepted abstracts!
WHY SHOULD YOU ATTEND?
• This workshop is intended as a compact, focused meeting to encourage crossdisciplinary scientific dialogue and in-depth discussions among all attendees, including presenters.
• This meeting is a stepping stone for young medical professionals to present their research in an informal and encouraging setting. We encourage their participation by offering them a complimentary registration (for more information see meeting website).
• You will have a great opportunity to meet your international colleagues and expand your network in the beautiful surroundings of Amsterdam!
WHO SHOULD ATTEND?
Medical oncologists, internal medicine doctors, clinical pharmacologists, hospital pharmacists, industry researchers, government representatives and other experts involved in this field of research.
ABSTRACT SUBMISSION
We invite you to submit your research on the following topics:
• Pharmacokinetics and Pharmacodynamics of Approved and New targeted oncolytics
• Population pharmacokinetics & pharmacokinetic-pharmacodynamic modeling
• Drug development and optimization: approaches & tools
• Drug-drug and drug-disease state interactions
• Targeted oncolytics therapies in special populations
Abstract submission deadline: 1 February 2015
expertmedical events
www.expertmedicalevents.comREGISTRATION, ABSTRACT SUBMISSION AND GENERAL INFORMATION:
MONDAY 23 MARCH
08.00h Registration
09.00h Opening of the Workshop
Session 1 How to select the right drug and the right dose for the individual patient
09.15h Pharmacology as a tool to dose individualize cancer therapy Mark Ratain, MDUniversity of Chicago, USA
09.45h Early biomarkers as a tool to dose individualize cancer therapyTimothy Yap, MD, PhDInstitute of Cancer Research, United Kingdom
10.15h Discussion
10.45h Coffee Break
Session 2
11.15h Obstacles to use dose optimization in an early stage of cancer drug develohent René Bruno, PhDPharsight, France
11.45h Abstract - driven presentations
12.45h Discussion
13.00h Lunch
Session 3 Dose individualization is commonly and successfully used in other diseases - what can we learn
14.00h The revenues of dose individualization in other disciplines: HIV therapyCourtney Fletcher, PharmD (TBC)University of Nebraska, USA
14.30h Is cancer different? The first steps to dose individualize and optimize anticancer therapy George Demetri, MDHarvard Medical School, USA
15.00h Discussion
15.30h Coffee Break
Session 4 Abstract driven presentations
16.00h Abstract - driven presentations
Session 5 Will dose-individualization have a positive impact on treatment benefit
17.00h Clinical Case - debate session
18.00h End of Plenary session
TUESDAY 24 MARCH
Session 6 Modeling as a tool to individualize the dose and to accelerate drug approval
08.30h Preclinical modeling (PB/PK modeling) as a tool for dose optimization and estimate the clinical relevance of drug interactions Joga Gobburu, PhD, FCP, MBA University of Maryland, USA
09.00h The use of PK/PD modeling early in drug development and for dose individualizing approachesLena Friberg, PharmD, PhDUppsala University, Sweden
09.30h Pro-Con Discussion
10.30h Coffee break & poster viewing
Session 7 Modeling and simulation approaches in oncology and drug interaction studies
11.30h Abstract - driven presentations
13.00h Lunch
Session 8
14.00h Incorporation of dose individualizing approaches in the treatment of cancer – can we learn from the successes in ALL. How will this apply for solid tumors?Jan Schellens, MD, PhD,The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, the Netherlands
14.30h Panel Discussion
15.30h Closure of the workshop
PROGRAM
Related Documents
